Home » Business News » 2012 » October » October 5, 2012

MorphoSys's Partner OncoMed Advances the HuCAL Antibody OMP-59R5 into Phase 1b/2 Clinical Trial in Pancreatic Cancer

October 5, 2012 - Martinsried, Germany And Munich, Germany

MorphoSys AG /MorphoSys's Partner OncoMed Advances the HuCAL Antibody OMP-59R5 into Phase1b/2Clinical Trial in Pancreatic Cancer Processed and transmitted by ThomsonReuters ONE.The issuer is solely responsible for the content of this announcement.

MorphoSys AG (FSE: MOR; Prime Standard Segment, TecDAX) announced todaythat itscollaboration partner OncoMed Pharmaceuticals has advanced the HuCALantibodyOMP-59R5 into the next stage of clinical development. OMP-59R5, which ispart ofOncoMed's Notch pathway collaboration with GlaxoSmithKline, is nowbeingevaluated in a Phase 1b/2 trial in the US in first-line advancedpancreaticcancer patients.

"We are excited to see this innovative HuCAL program advancing into thenextstage of clinical development. Today's news further underlines thatMorphoSys'spipeline has matured substantially and is today well balanced withseveralcompounds inmid- to late-stage clinical development," commented Dr. MarliesSproll, Chief Scientific Officer of MorphoSys AG. "OMP-59R5 represents themostadvanced HuCAL-based antibody program targeting a validated cancer stemcellpathway. Cancer stem cells potentially offer one of the most attractivetargetsfor attacking a range of tumor types, making this program an excitingadditionto the overall pipeline of HuCAL-based drugs."

In the Phase 1b/2 "ALPINE" trial (Antibody therapy in first-LinePancreaticcancer Investigating anti-Notch Efficacy and safety), OMP-59R5 is beingtestedin combination with gemcitabine in first-line advanced pancreaticcancerpatients. Following a Phase 1b safety run-in, a randomized Phase 2clinicaltrial will proceed in these patients to compare the efficacy ofstandard-of-caregemcitabine either with OMP-59R5 or with placebo. The primary endpointsof thePhase 2 part of the trial will be progression-free survival (PFS) inOMP-59R5arms compared to a placebo arm. The two primary endpoints will examinePFS inall patients, as well as in patients who have a particularbiomarker. Keysecondary and exploratory endpoints include overall survival, responserate, andsafety, and these endpoints will be assessed in all patients, as well asin thebiomarker positive subset of patients.

MorphoSys's clinical pipeline now comprises one program in phase 2/3clinicaldevelopment, nine in phase 2 and eleven in phase 1. Of these,four areproprietary, as yet un-partnered programs, namely MOR103, which hassuccessfullycompleted a phase 1b/2a trial in rheumatoid arthritis and a phase 1btrial inmultiple sclerosis, MOR208, which has completed a phase 1 trial forchroniclymphocytic leukemia and MOR202, which is in a phase 1/2a trial formultiplemyeloma.

About MorphoSys:

MorphoSys developed HuCAL, the most successful antibody library technologyinthe pharmaceutical industry. By successfully applying this and otherpatentedtechnologies, MorphoSys has become a leader in the field of therapeuticantibodies, one of the fastest-growing drug classes in human healthcare.Thecompany's AbD Serotec unit uses HuCAL and other antibody technologies togenerate superior monoclonal antibodies for research and diagnosticapplications.Together with its pharmaceutical partners, MorphoSys has built atherapeuticpipeline of more than 70 human antibody drug candidates for the treatmentofcancer, rheumatoid arthritis, and Alzheimer's disease, to name just a few.Withits ongoing commitment to new antibody technology and drug development,MorphoSys is focused on making the healthcare products of tomorrow.MorphoSys islisted on the Frankfurt Stock Exchange under the symbol MOR. For regularupdatesabout MorphoSys, visit

HuCAL®, HuCAL GOLD®, HuCAL PLATINUM®, CysDisplay®,RapMAT®, arYla®and Ylanthia® and 100 billion high potentials® are registeredtrademarks ofMorphoSys AG.

Slonomics® is a registered trademark of Sloning BioTechnologyGmbH, asubsidiary of MorphoSys AG.

This communication contains certain forward-looking statementsconcerning theMorphoSys group of companies. The forward-looking statements containedhereinrepresent the judgment of MorphoSys as of the date of this release andinvolverisks and uncertainties. Should actual conditions differ from theCompany'sassumptions, actual results and actions may differ from thoseanticipated.MorphoSys does not intend to update any of these forward-lookingstatements asfar as the wording of the relevant press release is concerned.

Media Release (PDF):

This announcement is distributed by Thomson Reuters on behalf ofThomson Reuters clients. The owner of this announcement warrants that:

(i) the releases contained herein are protected by copyright and other applicable laws; and

(ii) they are solely responsible for the content, accuracy and originality of the information contained therein.

Source: MorphoSys AG via Thomson Reuters ONE


For more information, please contact:

MorphoSys AG
Dr. Claudia Gutjahr-Loser
Head of Corporate Communications & IR
Tel: +49 (0) 89 / 899 27-122

Mario Brkulj
Senior Manager Corporate Communications & IR
Tel: +49 (0) 89 / 899 27-454

Jessica Kulpi
Specialist Corporate Communications & IR
Tel: +49 (0) 89 / 899 27-332

Email Contact


Comment on this story